CUMYL-PEGACLONE

CUMYL-PEGACLONE is a gamma-carboline based synthetic cannabinoid that has been sold as a designer drug. The gamma-carboline core structure seen in CUMYL-PEGACLONE had not previously been encountered in a designer cannabinoid, though it is similar in structure to other gamma-carboline cannabinoids disclosed by Bristol-Myers Squibb in 2001.

Legal status

Sweden's public health agency classified CUMYL-PEGACLONE as a narcotic substance, on January 18, 2019.
In the United States, the DEA has temporarily placed CUMYL-PEGACLONE into Schedule I status starting on December 12, 2023, for up to 2 years. On December 11, 2025, DEA filed for permanent placement of CUMYL-PEGACLONE into Schedule I. A 30-day public comment period on the proposal will close on 1/12/26.